Salix Pharmaceuticals Ltd (SLXP.O)
26.97USD
9 Feb 2010
$-0.13 (-0.48%)
$26.97
--
$27.47
$26.82
368,050
1,047,137
$29.91
$6.14
SLXP.O
About
Overall
| Beta: | 0.80 |
| Market Cap (Mil.): | $1,330.82 |
| Shares Outstanding (Mil.): | 49.34 |
| Annual Dividend: | 0.00 |
| Yield (%): | NA |
Financials
| SLXP.O | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 1.96 | 3.76 |
| EPS (TTM): | 16.12 | -- | -- |
| ROI: | -14.34 | 0.92 | 2.30 |
| ROE: | -18.97 | 1.27 | 2.82 |
U.S. FDA advisory meetings through March 25
THIS DIARY IS FILED AS THE FOOD AND DRUG ADMINISTRATION UPDATES ITS SCHEDULE. ALL TIMES EST/GMT except items after March 13, 2010, which are EDT/GMT.
U.S. FDA advisory meetings through March 25
THIS DIARY IS FILED AS THE FOOD AND DRUG ADMINISTRATION UPDATES ITS SCHEDULE. ALL TIMES EST/GMT except items after March 13, 2010, which are EDT/GMT.
U.S. FDA advisory meetings through March 25
THIS DIARY IS FILED AS THE FOOD AND DRUG ADMINISTRATION UPDATES ITS SCHEDULE. ALL TIMES EST/GMT except items after March 13 which are EDT/GMT.
U.S. FDA advisory meetings through March 25
THIS DIARY IS FILED AS THE FOOD AND DRUG ADMINISTRATION UPDATES ITS SCHEDULE. ALL TIMES EST/GMT except items after March 13, 2010, which are EDT/GMT.
U.S. FDA advisory meetings through March 25
LOCATION: Hilton, 8727 Colesville Road, Silver Spring, Md.
U.S. FDA advisory meetings through March 25
The committee will review and discuss recent information, including recent literature regarding the possible risks to the general public from intentional exposure to ultraviolet radiation (UV) from use of tanning lamps. There continues to be a growing body of literature showing association of skin cancer with use of tanning lamps and the committee will discuss this information and other information related to the association of UV and skin cancer (both melanoma and non-melanoma). The committee
UPDATE 1-Salix posts narrower-than-expected Q3 loss
Nov 9 (Reuters) - Salix Pharmaceuticals Ltd posted a narrower-than-expected quarterly loss as revenue from its traveller's diarrhoea drug Xifaxan doubled, but forecast fourth-quarter loss wider than market estimates.
Indian shares claw higher; Bharti, R Comm tumble
* Stronger European start lifts local stocks from early fall
Sliding telcos push Indian shares down 1 pct
* Bharti, Reliance Comm drop over 11 pct on falling tariffs
Growth prospects boost healthcare companies
NEW YORK (Reuters) - Small and midcap healthcare stocks were standout performers on improved earnings outlooks, helping major U.S. small-stock indexes outperform on Monday.
Competitors
| Price | Change | |
|---|---|---|
| GlaxoSmithKline plc (GSK.L) | £1,206.00 | -12.50 |
| Solvay S.A. (SOLB.BR) | €69.70 | +0.05 |
| The Procter & Gamble Company (PG.N) | $61.76 | +0.75 |
| Shire Plc. (SHP.L) | £1,249.00 | +2.00 |
| Shire Plc. (3159084.L) | -- | -- |
| Monsanto Company (MON.N) | $75.72 | +1.51 |
| Bayer AG (BAYGn.DE) | €48.28 | +0.44 |
| Bayer AG (BAYE.F) | -- | -- |
| Prometheus Laboratories Inc. (RXDX.OQ) | -- | -- |
| Ranbaxy Laboratories Limited (RANB.BO) | Rs408.80 | +3.25 |
Earnings vs 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
